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Introduction: The aim of this analysis (AIRC-MFAG project no. 
14282) was to define a risk classification for resected squamous-cell 
lung cancer based on the combination of clinicopathological predic-
tors to provide a practical tool to evaluate patients’ prognosis.
Methods: Clinicopathological data were retrospectively correlated 
to disease-free/cancer-specific/overall survival (DFS/CSS/OS) using 
a Cox model. Individual patient probability was estimated by logis-
tic equation. A continuous score to identify risk classes was derived 
according to model ratios and dichotomized according to prognosis 
with receiver operating characteristic analysis.
Results: Data from 573 patients from five institutions were gathered. 
Four hundred ninety-four patients were evaluable for clinical analysis 
(median age: 68 years; male/female: 403/91; T-descriptor according 
to TNM 7th edition 1–2/3–4: 330/164; nodes 0/>0: 339/155; stages I 
and II/III and IV: 357/137). At multivariate analysis, age, T-descriptor 
according to TNM 7th edition, nodes, and grading were independent 
predictors for DFS and OS; the same factors, except age and grad-
ing, predicted CSS. Multivariate model predict individual patient 
probability with high prognostic accuracy (0.67 for DFS). On the basis 
of receiver operating characteristic-derived cutoff, a two-class model 
significantly differentiated low-risk and high-risk patients for 3-year 
DFS (64.6% and 32.4%, p < 0.0001), CSS (84.4% and 44.5%, p < 
0.0001), and OS (77.3% and 38.8%, p < 0.0001). A three-class model 
separated low-risk, intermediate-risk, and high-risk patients for 3-year 
DFS (64.6%, 39.8%, and 21.8%, p < 0.0001), CSS (84.4%, 55.4%, and 
30.9%, p < 0.0001), and OS (77.3%, 47.9%, and 27.2%, p < 0.0001).
Conclusions: A risk stratification model including often adopted 
clinicopathological parameters accurately separates resected squa-
mous-cell lung cancer patients into different risk classes. The project 
is currently ongoing to integrate the clinicopathological model with 
investigational molecular predictors.
Key Words: Squamous lung cancer, Prognosis, Prognostic model, 
Clinicopathological predictors.
(J Thorac Oncol. 2015;10: 1341–1348)
Despite the major advances in the personalized treatment of non–small-cell lung cancer (NSCLC), effective tar-
geted therapies for the squamous lung cancer subtype (SQLC, 
approximately the 25% of NSCLC) still lack. Particularly, in 
the context of adenocarcinoma, reliable evidences are avail-
able suggesting that cancer development and progression may 
be addicted through aberrant pathways specifically triggered 
by genetic abnormalities, constitutively acting as oncogenic 
drivers. Emblematic examples of such dependency are rep-
resented by EGFR mutant1–3 and ALK positive adenocarci-
noma,4 whereas the treatment with their specific tyrosine 
kinase inhibitors significantly contribute to improve progno-
sis, disease control, symptoms, and quality of life when com-
pared with traditional chemotherapy.
Besides these major advances for adenocarcinoma, 
SQLC still requires the identification and validation of a reli-
able clinicopathological and molecular portrait, to better strat-
ify SQLC patients according to prognosis and to predict their 
potential susceptibility to specific targeted treatments.
Regarding candidate clinicopathological factors, the 
tumor, node, metastasis (TNM) stage represents the most 
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reliable prognostic predictor in NSCLC patients.5 In addition to 
the TNM staging, the prognostic significance of the predominant 
histologic patterns has been validated in lung adenocarcinoma, 
whereas any similar prognostic role has been observed for his-
tological subtyping of SQLC (ie, keratinizing, nonkeratinizing, 
basaloid, and clear cell subtypes).6,7 However, in this uncertain 
landscape, several investigated pathological factors (including 
single cell invasion, tumor budding, nuclear diameter, number 
of metastatic lymph nodes, lymphatic/vascular and pleural inva-
sion) demonstrated a potential prognostic role in different series 
of resected SQLC (R-SQLC), retrospectively analyzed.8–10
With regard to molecular abnormalities, the Cancer 
Genome Atlas Research Project recently published the largest 
genomic characterization of SQLC, providing a comprehensive 
landscape of genomic and epigenomic alterations featuring the 
early stage of the disease. This study validated the existence of 
potentially druggable genes or pathways and provided the first in 
vivo evidence of the mutual exclusivity of genomic alterations.11
The general aim of our project was to create a prognostic 
nomogram for R-SQLC on the basis of validated and putative 
biomarkers, which may directly determine patient predictions, 
risk stratification, and treatment assignment with targeted 
agents, according to the emerged findings in the preclini-
cal setting. This strategy, may thus successfully integrate the 
known clinical findings with the newest genetic acquisitions 
into prognostic (and hopefully) predictive nomograms. In this 
regard, a risk classification for R-SQLC according to the com-
bination of clinicopathological predictors has been accom-
plished, to identify the best and worst prognostic performers.
MATERIALS AND METHODS
A step-by-step protocol was followed according to the 
methodological approach for building a nomogram for can-
cer prognosis proposed by Iasonos et al.12 with respect to the 
Reporting Recommendations for Tumor Marker Prognostic 
Studies (REMARK) criteria for the conduction of a retrospec-
tive study in the context of an unselected population.13,14
Patients’ Population
R-SQLC cases with stored tissue available for biomolecu-
lar analyses with at least 2 years of follow-up from the removal 
of the primary tumor, who underwent surgery since 2009 in five 
Italian institutions (University of Verona; Regina Elena National 
Cancer Institute, Rome; University of Torino; University of 
Perugia; University-Foundation of Chieti), were considered eli-
gible. A merged database of data was accomplished. Pathological 
diagnosis was made according to the World Health Organization 
classification and the American Joint Committee on Cancer; 
the Union for International Cancer Control TNM system (7th 
 edition) for lung cancer was applied for disease staging.
End Points
The aim of this analysis (Italian Association for Cancer 
Research, AIRC, first step of the MFAG project no. 14282) 
was to develop and validate a clinicopathological prognostic 
risk-class model to identify the best and worst performers 
in the context of a multicenter population of R-SQLC. The 
model was developed on the basis of a multivariate analysis 
exploring the independent impact of clinicopathological fac-
tors on overall survival (OS, time between diagnosis and death 
for any cause), cancer-specific survival (CSS, time between 
diagnosis and death due to cancer progression), and disease-
free survival (DFS, time between diagnosis and local/distant 
recurrence, onset of secondary cancer or death for any cause).
Statistical Analysis
Descriptive statistics was used to summarize pertinent 
study information. Follow-up was analyzed and reported accord-
ing to Shuster.15 Associations between variables were analyzed 
according to the Pearson χ2 test. The hazard ratio (HR) and the 
95% confidence intervals (95% CI) were estimated using the 
Cox univariate model.16 A multivariate proportional hazard 
model was developed using stepwise regression (forward selec-
tion, enter limit and remove limit, p = 0.10 and p = 0.15, respec-
tively), to identify independent predictors of outcomes. The 
assessment of interactions between significant investigational 
variables was taken into account when developing the multivari-
ate model. In presence of nonlinear distribution of ratios of con-
tinuous variables, the receiver operating characteristic (ROC) 
curve analysis was adopted for dichotomization according to the 
three outcomes (OS, CSS, and DFS).17,18 The ROC curve anal-
ysis allowed to estimate the area under the curve (AUC) with 
standard error (SE) and 95% CI, to provide a list of sensitivity, 
specificity, likelihood ratios, and positive and negative predic-
tive values for all possible threshold values and to calculate the 
difference between the areas under the ROC curves, with SE, 
95% CI and p value.19 OS, CSS, and DFS were calculated by the 
Kaplan–Meier product limit method from the date of the surgery 
until relapse, death due to cancer, and/or death for any cause. 
Curves were reported for those prognostic factors that resulted 
independent at the multivariate analysis. The log-rank test was 
used to assess differences between subgroups. Significance was 
defined at the p less than 0.05 level. The SPSS (version 18.0; 
SPSS, Inc., Chicago, IL), R (version 2.6.1; R Foundation for 
Statistical Computing, Vienna, Austria), and MedCalc (version 
14.2.1; MedCalc software, Ostend, Belgium) licensed statistical 
programs were used for all analyses.
Prognostic Score Assessment
The log-HR obtained from the Cox model was used to 
derive weighting factors of a continuous prognostic index, 
aimed to identify differential outcomes’ risks. Coefficients 
estimates were “normalized” dividing by the smallest one and 
rounding the resulting ratios to the nearest integer value.20 
Thus, a continuous score assigning to patients an “individual-
ized” risk was generated. Two different methods were adopted 
to derive risk classes21: (i) for model A, the score was dichoto-
mized according to prognosis with the ROC analysis (the best 
“splitter” cutoff is determined)17; (ii) for model B, patients’ 
outcomes (OS, CSS, and DFS) were displayed by dividing 
patients into three risk classes, by considering cutoffs chosen 
at approximately equal distance along the range of values.20
Internal Validation Analysis
To address the multivariate model overfit and to vali-
date the results, a cross-validation technique, which evaluates 
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the replication stability of the final Cox multivariate model in 
predicting all outcomes, was also investigated, using a resa-
mpling procedure.12,22,23 This technique generates a number 
of simulation datasets (at least 100, each approximately 80% 
of the original size), by randomly selecting patients from the 
original sample, to establish the consistency of the model 
across less-powered patient’ samples. Risk classes was gener-
ated on the basis of the combination of the found risk factors. 
The ROC analysis allowed to assess the predictive accuracy of 
the prognostic model, by the AUC determination.19
The Harrell’s guidelines for the identification of the 
correct number of covariates were taken into account for the 
power analysis (the number of deaths should have be more 
than 10 times greater than the number of investigated predic-
tors, so that the expected error from the Cox model would be 
less than 10%).24
The whole project (AIRC-MFAG Project 14282) was 
approved by the local Ethics Committee.
RESULTS
Patients
Data from 573 patients from five different Italian insti-
tutions were gathered. Four hundred ninety-four patients 
were evaluable for the clinical analysis, with an attrition rate 
of 13.7% (the clinical or pathological descriptors for survival 
analysis were missing in 79 patients). Median age was 68 years 
(range, 32–83 years). According to a previous model indicating 
the independent role of the overall number of the resected nodes 
(with the cutoff of 10) in determining the prognosis of such 
patients, this parameter was considered for the survival analysis 
in the univariate and multivariate models.18 As a clinical descrip-
tor, the median number of resected nodes was 13 (range, 1–62). 
The adopted T-factor status (T-descriptor according to TNM 
7th edition) incorporates all the pertinent T-descriptors (tumor 
size, status of pleural invasion, or intrapulmonary metastasis). 
Overall patients’ characteristics are shown in Table 1.
Survival Analysis
Median follow-up was 28 months (range, 1–213 
months, 53 months if calculated with the reverse method).25 
The overall number of deaths was 202 (164 due to cancer, 
38 due to other causes). Median DFS, CSS, and OS were 38 
months (95% CI: 31–45), 81 months (95% CI: 50–112), and 
58 months (95% CI: 42–74), with a 5-year rate of 38.6%, 
55.8%, and 48.6%, respectively. At the multivariate analysis, 
age 68 years or younger, T-descriptor according to TNM 7th 
edition 1–2, negative nodes, and grading 1–2 were significant 
independent predictors for longer DFS and OS. With regard to 
CSS, T-descriptor according to TNM 7th edition 1–2 and neg-
ative nodes were significant prognostic predictors (Table 2; 
Supplementary Fig. 1–3, Supplemental Digital Content, 
http://links.lww.com/JTO/A858).
Internal Validation Analysis
At the cross-validation analysis, nodes, grading, 
T-descriptor according to TNM 7th edition, and age were con-
firmed as independent factors for DFS (replication rate: 98%, 
72%, 70%, and 86%, respectively). The same factors were 
confirmed to be independent predictors for OS at the inter-
nal validation (replication rate: 100%, 98%, 100%, and 100% 
for nodes, grading, T-descriptor, and age, respectively). For 
what concerns CSS, at the cross-validation analysis nodes and 
T-descriptor were confirmed as independent predictors (repli-
cation rate: 93% and 93%, respectively).
Prognostic Score and Model Performance
According to the HRs obtained at the multivariate anal-
ysis, a prognostic scoring index was assigned to each patient 
to identify the individual risk of recurrence (Table 3).
TABLE 1.  Patients’ Characteristics (494 Evaluable Patients 
for the Clinical Analysis)
Patients Number (%)
Gender
  Male 403 (81.6)
  Female 91 (18.4)
T descriptor according to TNM 7th edition
  1 132 (26.7)
  2 227 (46.0)
  3 106 (21.6)
  4 29 (5.7)
TNM staging
  I 259 (52.4)
  II 118 (23.9)
  III 102 (19.4)
  IV 15 (2.4)
Lymph nodes
  Negative 339 (68.6)
  Positive 155 (31.4)
Resected lymph nodes
  <10 133 (26.9)
  ≥10 361 (73.1)
N status (N descriptor according to TNM 7th edition)
  0 339 (68.6)
  1 65 (13.2)
  2 63 (12.8)
  3 27 (5.4)
Grading
  G 1–2 219 (44.3)
  G 3 177 (35.9)
  Unknown 98 (19.8)
Chemotherapy
  Neoadjuvant 26 (5.2)
  Adjuvant 75 (15.2)
  None 272 (55.1)
  Unknown 121 (24.5)
Surgery
  Lobectomy 308 (62.3)
  Bilobectomy 45 (9.1)
  Pneumonectomy 74 (15.0)
  Unknown 67 (13.6)
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The score dichotomization according to outcome, 
derived from the ROC analysis and the maximally selected 
log-rank statistics, identified 2 as the optimal cutoff point. 
According to the two-class model (model A), a statistically 
significant prognostic difference between patients at low 
(score ≤2) and high risk (score >2) was determined for both 
DFS (3-year: 64.6% and 32.4%, p < 0.0001; 5-year: 52.5% 
and 15.1%; p < 0.0001), CSS (3-year: 84.4% and 44.5%, 
p < 0.0001; 5-year: 78.8% and 24.5%; p < 0.0001), and OS 
(3-year: 77.3% and 38.8%, p < 0.0001; 5-year: 67.6% and 
17.0%; p < 0.0001; Fig. 1).
On the basis of the outcome, patients were divided 
into three risk classes, by considering cutoffs chosen at 
approximately equal distance along the range of values: (1) 
low risk of recurrence and death: score 0–2 (ie, the best 
outcome estimate); (2) intermediate risk of recurrence and 
death: score 3–4; (3) high risk of recurrence and death: 
score 5–6 (ie, worst outcome estimate). According to the 
three-class model (model B), a highly significant prog-
nostic difference between patients at low, intermediate, 
and high risk was found for DFS (3-year: 64.6%, 39.8%, 
and 21.8%, p < 0.0001; 5-year: 52.5%, 23.2%, and 6.2%, 
p < 0.0001), CSS (3-year: 84.4%, 55.4%, and 30.9%, 
p < 0.0001; 5-year: 78.8%, 35.0%, and 15.5%, p < 0.0001), 
and OS (3-year: 77.3%, 47.9%, and 27.2%, p < 0.0001; 
5-year: 67.6%, 25.4%, and 9.1%, p < 0.0001; Fig. 1).
No difference in the prognostic models’ performance 
according to ROC analysis was found. For DFS, the AUC 
values were 0.65 (SE, 0.03) in model A (two classes) and 
0.67 (SE, 0.03) in model B (three classes) with a sensitivity 
of 0.54 and a specificity of 0.77 for both the models (Fig. 2). 
The AUC values for OS were 0.72 (SE, 0.04; sensitivity, 
0.74; specificity, 0.67) in model A and 0.72 (SE, 0.03; sen-
sitivity, 0.66; specificity, 0.74) in model B. The AUC values 
for CSS were 0.71 (SE, 0.04; sensitivity, 0.74; specificity, 
0.67) in model A and 0.70 (SE, 0.03; sensitivity 0.74; speci-
ficity, 0.67) in model B.
DISCUSSION
The results of the analysis reported herein indicate that 
the combination of a series of simple, known, and easy-to-use 
clinicopathological factors is able to significantly discriminate 
the prognosis of patients resected for SQLC. These factors 
may be combined in a prognostic tool and allow a stratifica-
tion of patients in two or three risk classes, with a moderately 
significant prognostic accuracy.26TA
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TABLE 3.  Prognostic Score Assessment According to 
Disease-Free Survival
Disease-Free Survival
Score Points
0 1 2
Age ≤68 >68 —
T-descriptor according to TNM 7th edition 1–2 — 3–4
Lymph nodes Negative — Positive
Grading 1–2 3 —
TNM, tumor, node, metastasis.
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These data may help to complement a clinical area, 
whereas the identification and validation of reliable fac-
tors influencing the prognosis of R-SQLC in the context of 
modern medicine still represent a matter of research. Indeed, 
although lung cancer represents the most common cause of 
cancer-related death worldwide and SQLC account for 20% to 
30% of NSCLC; nowadays, the pathological stage (TNM) still 
represents the most reliable prognostic predictor.5
Many previous studies have been performed to evaluate 
various clinicopathological prognostic factors other than the 
pathological stage for resected NSCLC patients. Age, gender, 
and T-descriptor according to TNM 7th edition are widely 
validated predictors, able to significantly contribute to indi-
vidualized prediction of survival.27–29
For that concern lymph nodes status, most studies sup-
port the relationship between higher number of examined 
lymph nodes and better survival.18,30–32 These results suggest 
the rationale that the examination of a greater number of 
lymph nodes in patients with early-stage NSCLC may not only 
positively affect patients’ outcome removing potential metas-
tasized lymph nodes, but also increasing the likelihood of a 
proper staging and, therefore, of an appropriate therapeutic 
FIGURE 1.  Disease-free survival  
(A and B), cancer-specific survival  
(C and D), and overall survival (E and F),  
according to risk classes as developed 
for model A (A, C, and E) and model 
B (B, D, and F ). The 5-year rate for 
each outcome is reported, p value at 
long-rank analysis.
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approach. In this regard, the number of metastatic nodes (more 
than the location-based pN stage) seems to be determinant to 
influence the survival of resected NSCLC patients.10
The prognostic significance of different histological 
patterns, although recognized and validated for lung adeno-
carcinoma,6,7 has not been demonstrated in SQLC. In fact, 
published data on the prognosis of basaloid/nonbasaloid 
subtypes and according to the degree of keratinization of 
SQLC, which represent the most investigated pathological 
factors, are still controversial, and further investigations are 
required. Kadota et al.8 retrospectively analyzed a large series 
of patients with R-SQLC, investigating whether any included 
pathological factors (tumor differentiation, histologic subtype, 
tumor nest size, and nuclear grade) correlated with outcomes 
(OS and DFS), independently of the pathological stage. In 
multivariate analysis, single cell invasion, nuclear diameter, 
and tumor budding were independent prognostic predictors of 
OS, whereas the histologic subtyping did not show prognostic 
significance. Tumor budding represents a recognized morpho-
logical pattern of tumor invasion, identified as an unfavorable 
prognostic indicator in colorectal cancer, lung adenocarci-
noma, and SQLC.33
Others recognized predictors of prognosis in the SQLC 
are represented by the lymphatic invasion9 and the pathologi-
cally proven vascular/pleural invasion that seems to influence 
both the risk of recurrence and death of SQLC patients,34 par-
ticularly those affected by a peripheral carcinoma.35
Tumor grading is a reliable predictor of survival in a 
broad variety of solid human tumors including lung cancer,36 
and in some cases, such as breast cancer and prostate cancer, 
its evaluation may influence the main therapeutic approach. 
Nevertheless, considering that the methods for assessing 
tumor grading are variables and that this predictor is a com-
posed parameter including a series of additional factors (such 
as the histopathological subtype, the proportion of the lepidic 
part, and the nuclear size), the potential biases deriving from 
the subjective assessment and the interobserver variability 
among pathologists have to be considered. At this regard, 
some studies have estimated and evaluated the interobserver 
variability of grading in lung adenocarcinoma, demonstrating 
the existence of an high agreement among pathologists for 
nuclear grading (higher than for histological classifications 
and the extent of the lepidic pattern), supporting the rationale 
that this parameter may be currently applicable with accept-
able interobserver variability if performed by specifically 
trained pathologists.37,38
Although, as reported, several studies have examined 
the potential correlation between clinical or pathological 
markers and survival, to date only one prognostic nomogram, 
based on the combination of multiple parameters, has been 
recently validated in resected NSCLC. Liang et al.39 estab-
lished and validated the first nomogram for predicting survival 
of patients with resected NSCLC based on a large database 
with long-term follow-up. Six independent prognostic factors 
were identified and included in the prognostic model (age, 
sex, histology, number of obtained lymph nodes, T category, 
and N category). The novel nomogram may help clinicians to 
estimate the survival of resected NSCLC patients and to iden-
tify those subgroups of patients more probable to benefit from 
a specific adjuvant treatment strategy.39
In our study, we retrospectively investigated a series of 
clinicopathological factors with a putative prognostic role in 
573 patients undergoing thoracic surgery for a SQLC (494 
available for the clinical analysis), to establish their poten-
tial value as survival predictors. This risk classification sys-
tem, comprising the often adopted clinical and pathological 
parameters (age, T-descriptor according to TNM 7th edition, 
nodes, and grading), was able to accurately separate R-SQLC 
patients according to their individual risk of recurrence, 
death from cancer, and death for any cause, regardless of the 
adopted method (Fig. 1). As a major finding, our multivari-
ate model was capable to significantly predict the individual 
risk of recurrence with a moderate prognostic accuracy (0.67). 
To overcome the potential bias of the retrospective nature of 
this model, a cross-validation analysis did demonstrate that 
the independent factors significantly replicate with a high rate.
Once established the accuracy of the model, the extrap-
olated continuous prognostic score demonstrated to carefully 
stratify R-SQLC patients in two or three classes (on the basis 
of the adopted method for the cutoff identification), according 
to their life expectancy (Table 3). Nevertheless, taking into 
account the retrospective nature of our data and the potential 
biases deriving from the analysis of a surgically heterogeneous 
cohort of patients (gathered from five different institutions), 
FIGURE 2.  Model’s prognostic per-
formance of model A (A) and model 
B (B) for disease-free survival. AUC, 
area under the curve; SE, standard 
error.
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results should be interpreted cautiously and definitive conclu-
sions should be delayed to the prospective validation of the 
model. Moreover, the prognostic parameters investigated in 
this study were not novel compared with previous studies, 
even though the combinations of these factors were able to 
significantly discriminate between the prognosis of patients 
with R-SQLC.
To our knowledge, this is the first prognostic nomo-
gram built selectively for a population of patients affected by 
the squamous histotype of lung cancer. The recent publica-
tion of the first nomogram for predicting survival of patients 
with resected NSCLC39 indirectly supports the rationale and 
the results of our analysis. Indeed, the study of Liang et al.39 
confirmed the reliability of a prognostic nomogram based on 
some of the same clinicopathological predictors detected in 
our study (age, T-descriptor, and lymph nodes status).
The ideal perspective is to borrow a patient-centered 
diagnostic–therapeutic approach in the context of SQLC, 
analogously of those widely employed for adenocarcinoma. 
The introduction and validation of a personalized approach 
may help the clinicians to provide the best available therapy 
for that specific patient to potentiate the expected clinical ben-
efit and reduce the human and economic cost resulting from a 
less efficacious not-targeted treatment.
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